Showing 1 - 20 of 939 Items
Showing 1 - 20 of 939 Items
Sort By: Relevance
Science Portal
v2.1.5758.produseast1
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
BACKGROUND
Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the p...
INTRODUCTION
In 2023, almost 200,000 children under 15 years died from tuberculosis, most without appropriate treatment. Treatment decision algorithms (TDAs), d...
People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with those who do not, but the pathways explaining this effect are unclear. We esti...
RATIONALE
Recent empirical research suggests isoniazid may lead to a risk reduction ...
INTRODUCTION
In 2022, the WHO conditionally recommended the use of treatment decision algorithms (TDAs) for treatment decision-making in children <10 years with...
BACKGROUND
The ‘CaP-TB’ project enhanced paediatric TB care through decentralized services, including screening, specimen collection, chest X-rays and implement...
BACKGROUND
Strains of Mycobacterium tuberculosis
BACKGROUND
Dru...
BACKGROUND
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...
BACKGROUND
In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...
Each day more than 500 children younger than 15 years die from tuberculosis. Considerable progress has been...
This case report presents a rare instance of concomitant splenic tuberculosis (TB), Epstein–Barr virus (EBV)-related T-cell leukemia/lymphoma, and malaria in a 28-year-old pregnant wo...
BACKGROUND
The optimal dosing strategy of linezolid for treating multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remains unclear. We condu...
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médec...
BACKGROUND
The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...